Enterprise business software provider Aptean has partnered with CAS, a division of the American Chemical Society, to make CAS Biosequences content available on the GenomeQuest sequence search platform beginning in late March. Aptean GenomeQuest is an intellectual property (IP) sequence search tool that integrates the world's largest, most up-to-date IP sequence database with state-of-the-art sequence comparison algorithms for powerful patent sequence search and analysis. Adding the CAS Biosequences Module to the Aptean GenomeQuest platform provides an additional source of human-curated biosequence content disclosed in patents and journals, extending the comprehensiveness of biotechnology IP searches and providing efficiency for users by making both of these critical resources accessible through GenomeQuest's powerful, user-friendly interface.
The addition of the CAS Biosequences Module to GenomeQuest will give users direct access to CAS's broad, highly curated collection of sequences from both journal and patent publications. CAS's expert scientific analysts have generated unique content that specifically indexes chemical modifications to biosequences. This curated content allows users to quickly identify novel sequences both in patent claims as well as research studies.
GenomeQuest's powerful, web-based interactive analysis will enable searchers to write Boolean queries combining different percent identities with bibliographic and text terms to search this powerful combination of content-rich databases. While users previously had to search and analyze data sources separately, combine the results, and then deduplicate them, they will now be able to simultaneously search and analyze these critical content collections expediting their workflow and delivering new insights.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
